K. Modjarrad, Lin, L., George, S. L., Stephenson, K. E., Eckels, K. H., De La Barrera, R. A., Jarman, R. G., Sondergaard, E., Tennant, J., Ansel, J. L., Mills, K., Koren, M., Robb, M. L., Barrett, J., Thompson, J., Kosel, A. E., Dawson, P., Hale, A., C Tan, S., Walsh, S. R., Meyer, K. E., Brien, J., Crowell, T. A., Blazevic, A., Mosby, K., Larocca, R. A., Abbink, P., Boyd, M., Bricault, C. A., Seaman, M. S., Basil, A., Walsh, M., Tonwe, V., Hoft, D. F., Thomas, S. J., Barouch, D. H., and Michael, N. L.,
“Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.”,
Lancet, vol. 391, no. 10120, pp. 563-571, 2018.
]